Clinical Trials Logo

Rosacea clinical trials

View clinical trials related to Rosacea.

Filter by:

NCT ID: NCT00940992 Completed - Rosacea Clinical Trials

A Study of DER 45-EV Gel to Treat Rosacea

SGTDER45EV
Start date: January 2012
Phase: Phase 2
Study type: Interventional

To identify lowest efficacious dose of DER 45 EV Gel, 1% and 5% verses vehicle in patients with rosacea.

NCT ID: NCT00892281 Completed - Rosacea Clinical Trials

ORCA - Oracea® for Rosacea: A Community-based Assessment

Start date: April 2009
Phase: Phase 4
Study type: Interventional

The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.

NCT ID: NCT00882531 Completed - Clinical trials for Papular-pustular Rosacea

Isotretinoin in Papular-Pustular Rosacea

ISOROS
Start date: February 2007
Phase: Phase 3
Study type: Interventional

A national, multicentre, prospective, randomised, double-blind, phase III study in 2 parallel groups of isotretinoin versus placebo in patients presenting papular-pustular rosacea resistant to standard therapy. A non-balanced group (2 isotretinoin /1 placebo) design was selected since, given the nature of the study disease, fewer patients will receive the placebo than active isotretinoin. Treatment duration for each patient : 4 months, with monthly evaluation Follow-up at 2 months and 4 months for patients responsive after 4 months of treatment.

NCT ID: NCT00855595 Completed - Clinical trials for Papulopustular Rosacea

Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea

Start date: February 2009
Phase: Phase 4
Study type: Interventional

Subjects with moderate papulopustular rosacea will be treated either with azelaic acid 15% gel topically plus an anti-inflammatory dose of doxycyline (40mg) daily or with metronidazole 1% gel topically once daily plus an anti-inflammatory dose of doxycycline (40mg) over at total of twelve weeks to determine the rapidity of improvement, and the length of time to reach 25%, 50% and 75% clearing compared to baseline.

NCT ID: NCT00823901 Completed - Rosacea Clinical Trials

Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea

Start date: February 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel are effective and safe in the treatment of papulopustular rosacea.

NCT ID: NCT00710489 Completed - Psoriasis Clinical Trials

Potential Research Study Participant Registry

Start date: May 2008
Phase:
Study type: Observational

The purpose of the potential research study participant registry is to keep potential research subjects informed about any future research studies in which they may meet the criteria for enrollment. The purpose of this study is also to assist current and future clinical trials with recruitment of subjects.

NCT ID: NCT00697541 Completed - Clinical trials for Erythematous Rosacea

Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

Start date: May 2008
Phase: Phase 2
Study type: Interventional

Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%

NCT ID: NCT00681603 Completed - Rosacea Clinical Trials

Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization

Start date: August 2007
Phase: N/A
Study type: Interventional

1. Purpose:Our animal study demonstrated the effectiveness of subconjunctival injection of bevacizumab in the inhibition of corneal neovasculization formation. The purpose of this human interventional study is to report the treatment outcome of subconjunctival injection of bevacizumab in patients with corneal neovascularization. 2. Material and methods: We enrolled 13 patients with unilateral or bilateral clinically significant corneal neovascularization during Aug. 2007 to Jan. 2008. Subconjunctival injection of bevacizumab once per month for at most 7 times was performed according to clinical response. 3. Main outcome measurements: resolution of corneal neovascularization, reduction of lipid infiltrate, improved visual acuity.

NCT ID: NCT00668655 Completed - Rosacea Clinical Trials

An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%

Start date: February 2008
Phase:
Study type: Observational

The purpose of this study is to determine the cosmetic appearance of metronidazole gel (MetroGel®) 1% with commonly marketed facial foundations.

NCT ID: NCT00667173 Completed - Rosacea Clinical Trials

A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of IDP-115 in treating patients with rosacea.